FDA Lifts Partial Clinical Hold on Vanda Pharmaceuticals' Tradipitant for Motion Sickness
The FDA has lifted the partial clinical hold on Vanda Pharmaceuticals' protocol for tradipitant, allowing more than 90 doses for motion sickness. This follows Vanda's dispute resolution request and expedited FDA re-review. Vanda is continuing clinical development and seeking FDA approval for tradipitant to prevent motion-induced vomiting.
Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its protocol VP-VLY-686-3403, which previously limited the administration of tradipitant for motion sickness to a maximum of 90 doses. This decision follows Vanda’s formal dispute resolution request and an expedited re-review by the FDA. The company is pursuing further clinical development and potential FDA approval of tradipitant for the prevention of vomiting induced by motion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH39909) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
